Gold prices set for weekly drop as dollar surges; Trump tariff action in focus
On Wednesday, Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company’s price target. The new target has been set at $206.00, a decrease from the previous figure of $292.00. Despite this adjustment, the firm maintains an Overweight rating on the biotechnology company’s stock. Currently trading at $145.63, the stock sits near its 52-week low of $139.71, while InvestingPro data reveals that 10 analysts have recently revised their earnings expectations downward for the upcoming period.
The reassessment by Cantor Fitzgerald was prompted by a detailed analysis of Biogen’s valuation, taking into account various potential scenarios. According to the firm, there seems to be a disconnect in the market’s understanding of Biogen’s financial outlook, particularly concerning royalty streams and revenue projections.
One of the key issues identified is the Street’s current modeling of CD20 royalties, which Cantor Fitzgerald believes has been inaccurately represented. Additionally, the firm suggests that the consensus estimates for Leqembi, Biogen’s Alzheimer’s drug, might still be overly optimistic.
Despite these concerns, Cantor Fitzgerald’s stance on Biogen’s stock remains positive. The firm’s analysts argue that Biogen’s shares are trading at an attractive price, which they consider to be undervalued, even when conservative revenue estimates are applied. This assessment aligns with InvestingPro analysis, which indicates the stock is currently undervalued, with a P/E ratio of 12.83 and strong free cash flow yield. Discover more insights about Biogen’s valuation and 12 additional ProTips with an InvestingPro subscription, including access to comprehensive Pro Research Reports covering 1,400+ top stocks.
Biogen, known for its work in neuroscience, including therapies for neurological and neurodegenerative diseases, has been closely watched by investors, especially following the development and launch of Leqembi. The adjustment in the price target reflects a recalibration of expectations based on the firm’s latest analysis of the company’s financial components.
Investors will continue to monitor Biogen’s performance in the market, particularly in light of Cantor Fitzgerald’s updated valuation and the ongoing discussion about the company’s revenue potential and royalty streams. With a market capitalization of $21.27 billion and annual revenue of $9.61 billion, Biogen maintains its position as a significant player in the biotechnology sector.
In other recent news, Sage Therapeutics has initiated a strategic review process and rejected an unsolicited acquisition proposal from Biogen Inc. The company’s Board of Directors is exploring strategic alternatives to maximize shareholder value, with Goldman Sachs & Co. LLC serving as the financial advisor. Meanwhile, Ionis Pharmaceuticals (NASDAQ:IONS) announced that regulatory agencies in the United States and Europe have accepted applications for a higher dose regimen of its spinal muscular atrophy (SMA) drug, nusinersen, which is licensed by Biogen.
Simultaneously, Biogen is under review by the FDA and EMA for a higher dose regimen of the same SMA drug, nusinersen. The company has maintained a positive outlook with an Outperform rating from Oppenheimer, which highlighted Biogen’s disciplined growth strategy and potential for strategic capital allocation. In addition, Biogen appointed Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller, effective from March 1, 2025, signaling a strategic shift in the company’s finance leadership.
These recent developments illustrate the ongoing strategic efforts of both Sage Therapeutics and Biogen to maximize shareholder value and advance their respective drug offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.